CASI Pharmaceuticals, Inc.
CASIF · OTCMCIK 1962738fmd_1R8TGN1X4FSVKQRV2EM9ADP44PManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
Latest annual · FY2025
Millions- Total revenues
- 21
- Gross profit
- 10
- Operating income
- (45)
- Net income
- (48)
- Free cash flow
- (21)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -21.7%
- Revenue, 5 yearsFY2020 to FY2025
- +6.5%
- Net income, 5 yearsFY2020 to FY2025
- n/m
CASI Pharmaceuticals, Inc. (CASIF) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $20.7 million | $28.5 million | -27.4% | 20-F 2026-05-15 · proof |
| Gross profit | $10.1 million | $11.1 million | -9.6% | 20-F 2026-05-15 · proof |
| Operating income | -$45 million | -$39.6 million | 20-F 2026-05-15 · proof | |
| Net income | -$48.1 million | -$39.3 million | 20-F 2026-05-15 · proof | |
| Cash from operating activities | -$20.8 million | -$29.2 million | 20-F 2026-05-15 · proof | |
| Free cash flow | -$20.8 million | -$29.4 million | 20-F 2026-05-15 · proof | |
| Total assets | $25.7 million | $53.7 million | -52.2% | 20-F 2026-05-15 · proof |
| Total liabilities | $62.9 million | $51.8 million | +21.4% | 20-F 2026-05-15 · proof |
| Cash and cash equivalents | $5.6 million | $13.5 million | -58.2% | 20-F 2026-05-15 · proof |
- What was CASI Pharmaceuticals, Inc. (CASIF)'s revenue in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported revenue of $20.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $28.5 million the year before (-27.4%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was CASI Pharmaceuticals, Inc. (CASIF)'s gross profit in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported gross profit of $10.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $11.1 million the year before (-9.6%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was CASI Pharmaceuticals, Inc. (CASIF)'s operating income in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported operating income of -$45 million for fiscal 2025 (the year ended Dec 31, 2025), against -$39.6 million the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was CASI Pharmaceuticals, Inc. (CASIF)'s net income in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported net income of -$48.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$39.3 million the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was CASI Pharmaceuticals, Inc. (CASIF)'s cash from operating activities in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported cash from operating activities of -$20.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$29.2 million the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was CASI Pharmaceuticals, Inc. (CASIF)'s free cash flow in fiscal 2025?
- CASI Pharmaceuticals, Inc. (CASIF) reported free cash flow of -$20.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$29.4 million the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are CASI Pharmaceuticals, Inc. (CASIF)'s total assets?
- As of Dec 31, 2025, CASI Pharmaceuticals, Inc. (CASIF) reported total assets of $25.7 million, against $53.7 million a year earlier (-52.2%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are CASI Pharmaceuticals, Inc. (CASIF)'s total liabilities?
- As of Dec 31, 2025, CASI Pharmaceuticals, Inc. (CASIF) reported total liabilities of $62.9 million, against $51.8 million a year earlier (+21.4%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are CASI Pharmaceuticals, Inc. (CASIF)'s cash and cash equivalents?
- As of Dec 31, 2025, CASI Pharmaceuticals, Inc. (CASIF) reported cash and cash equivalents of $5.6 million, against $13.5 million a year earlier (-58.2%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CASIF&period_type=annual&limit=5"Information only, not investment advice.